Selank

The strongest human evidence for Selank is its comparison against medazepam in 62 patients with GAD and neurasthenia (Zozulya et al., 2008). Selank produced comparable reductions in Hamilton and Zung anxiety scale scores while additionally showing antiasthenic effects (reduced fatigue and weakness) and psychostimulant properties that medazepam did not produce. Critically, Selank did not produce sedation, cognitive impairment, or the motor coordination issues that even low-dose benzodiazepines typically cause. A 2015 study of 70 patients combining Selank with a benzodiazepine showed improved efficacy and reduced side effects compared to benzodiazepine alone. Acute effects — subjective anxiety reduction — occur within 10-30 minutes of intranasal dosing. Cumulative anxiolytic stabilization develops over 1-2 weeks of consistent daily use. Grade B based on the Russian clinical trial data (limited by non-independent provenance); Grade C for independent confidence given lack of external replication.

The nootropic evidence is primarily preclinical. Animal models consistently show Selank improving performance on learning and memory tasks — spatial navigation, conditioned avoidance, and recognition memory paradigms. The human clinical data shows cognitive preservation or mild enhancement as a secondary finding in the anxiety trials — primarily the absence of the cognitive impairment seen with benzodiazepines, plus some patients showing improved attention. Whether Selank produces meaningful cognitive enhancement in neurotypical individuals with no anxiety disorder is not addressed by any published human trial. This is a significant gap given that much of the Western community uses Selank specifically as a cognitive enhancement compound. Grade C-D (animal models; clinical data documents non-impairment more than active enhancement).

Neurasthenia is a diagnostic category recognized in Russian and Eastern European psychiatry that maps roughly onto what Western medicine might describe as chronic fatigue syndrome, burnout, or stress-related functional impairment. Selank's clinical approval covers both GAD and neurasthenia — conditions often co-occurring. The antiasthenic effects observed in the Zozulya trial (reduced fatigue, increased energy and motivation) are consistent with Selank's combination of anxiolytic and mild psychostimulant properties. For Western users, this maps onto the 'calm energy' or 'relaxed focus' quality that the community consistently describes as Selank's subjective signature. Grade B in the Russian clinical context; not independently validated.

Russian preclinical data shows Selank's BDNF-upregulating effects may help counter chronic alcohol's reduction of hippocampal BDNF — a mechanism implicated in alcohol-related cognitive impairment and dependency. Animal models show Selank reducing alcohol preference and attenuating some withdrawal behaviors. This application is largely theoretical for human use and has not been the subject of a dedicated clinical trial, but the mechanistic connection is plausible. Grade C-D.

Consistent with its tuftsin heritage, Selank influences innate immune function — macrophage activation, cytokine balance, interferons. This may contribute to overall stress resilience and is mechanistically coherent, but is not a primary therapeutic application and not a reason most community users choose Selank. Grade C (Russian studies; tuftsin immunology is independently established).

Selank is a synthetic heptapeptide: threonine-lysine-proline-arginine-proline-glycine-proline (TKPRPGP). Molecular weight approximately 791 Da. The N-terminal four residues (TKPR) correspond directly to tuftsin. The C-terminal Pro-Gly-Pro extension was engineered to resist prolyl oligopeptidase and other peptidases that rapidly degrade native tuftsin. The multiple proline residues throughout the sequence provide substantial conformational rigidity and peptidase resistance that give Selank a plasma half-life of approximately 2-5 minutes — short, but sufficient for downstream signaling effects lasting hours. The peptide exists as a white lyophilized powder and is highly water-soluble.

• Selank (standard, TKPRPGP): the compound studied in published clinical and preclinical research. Russian commercial formulation: 'Selank 0.15%' nasal drops (150 mcg per actuation), approved 2009. The compound in all referenced trials. This is what to use when 'Selank research' is the goal.
• N-Acetyl Selank Amidate (NA-Selank-A): an acetylated, C-terminally amidated analog. Claimed to have improved stability and altered pharmacokinetics. The evidence base for NA-Selank-A is substantially thinner than for standard Selank — most community discussion of it is extrapolated from Selank data, not from its own studies. The receptor binding profile may differ. These are not interchangeable compounds. COA mass spectrometry should confirm the correct molecular weight for whichever compound you source (~791 Da for Selank vs higher for acetylated form). Vendors sometimes substitute or relabel — confirm identity by mass spec.
• Selank + Semax combination products: pre-mixed intranasal formulations sold by some vendors. No published research on the combination. Mechanistically non-redundant (complementary mechanisms). Community preference for the combination is based on the logic that Selank provides the calm base and Semax provides the cognitive drive — neither interfering with the other.

Lyophilized Selank is stable for 18-24 months at -20C. Reconstituted for intranasal use, refrigerate at 2-8C and use within 30 days. Selank is particularly sensitive to heat and UV exposure in solution — store reconstituted product in an amber glass nasal spray bottle, refrigerated. Unlike GHK-Cu, there is no visual quality indicator; mass spectrometry is the only identity confirmation. Unlike BPC-157 or TB-500, oral use is contraindicated — Selank is destroyed by GI proteases before reaching systemic circulation.

The primary proposed anxiolytic mechanism is allosteric modulation of GABA-A receptors — the same receptor family targeted by benzodiazepines, but at a different binding site and with different downstream consequences. Benzodiazepines are positive allosteric modulators at the benzodiazepine site, producing sedation, muscle relaxation, and dependency through receptor downregulation with chronic use. Selank's modulation appears to occur at a distinct site, producing GABAergic stabilization without the sedation, tolerance, or physical dependence profile. The GABA modulation hypothesis is supported by animal pharmacology and the clinical anxiolytic effects, but a complete mechanistic account — identifying the specific binding site and the structural basis for the differing side effect profile — has not been published. Grade C-D (animal pharmacology + clinical concordance; binding site not fully characterized).

The most independently characterized and arguably most interesting mechanism is enkephalinase inhibition. Enkephalins are endogenous opioid peptides that regulate stress response, emotional state, and pain — the body's natural anxiolytic system. They are rapidly degraded by enkephalinase enzymes (including neprilysin and aminopeptidase N). Kost et al. (2001) [2] and Meshavkin et al. (2006) [3] demonstrated that Selank dose-dependently inhibits these enkephalin-degrading enzymes, with greater potency than established peptidase inhibitors bacitracin and puromycin. The clinical significance: patients with GAD were found to have shorter enkephalin half-lives correlated with anxiety severity. Selank treatment increased enkephalin half-life alongside anxiety reduction (Zozulya et al., 2008). The mechanism is mechanistically elegant and explains the 'clean' anxiolytic profile: instead of artificially agonizing GABA receptors, Selank extends the duration of the body's own anti-stress peptides. This does not require receptor agonism and avoids the tolerance/dependence pathway. Grade C (consistently documented; multiple Russian publications; mechanism is coherent; independent replication of the enkephalinase target itself has not occurred outside Russia).

BDNF (brain-derived neurotrophic factor) is the primary growth factor supporting neuron survival, synaptic plasticity, and memory formation. A 2017 study (Institute [6] of Molecular Genetics) found Selank administration increased BDNF mRNA expression by approximately 40% in hippocampal tissue in animal models, correlated with improved spatial memory performance and enhanced long-term potentiation. This BDNF-mediated effect is the primary mechanistic basis for Selank's nootropic properties and the hippocampus-targeted memory and learning benefits the community reports. The molecular cascade linking Selank's receptor interactions to BDNF transcription has not been fully resolved. Grade C-D (animal model; development institution; BDNF upregulation independently plausible given GABAergic mechanism — reduced chronic stress reliably increases hippocampal BDNF regardless of specific peptide mechanism).

One of the pharmacologically interesting features of Selank is that its serotonergic effects are state-dependent rather than unidirectional. Nadorova et al. found that under normal baseline conditions, Selank produces minimal changes in 5-HT or 5-HIAA (the primary serotonin metabolite). When serotonin is pathologically elevated — as occurs under chronic stress — Selank normalizes accumulation in the frontal cortex, hypothalamus, and amygdala. This bidirectional modulation rather than simple up- or downregulation is characteristic of homeostatic regulatory peptides rather than pharmaceutical agonists, and explains why Selank does not produce the flat emotional affect or sexual dysfunction associated with SSRI-class drugs that simply flood the serotonergic system. Grade C-D (animal model, development institution; state-dependency finding is important and clinically relevant if replicated in humans).

A transcriptomic study by Kasian (PMID: 26847159) found that Selank activates Drd5 gene expression — the dopamine D5 receptor. D5R activation plays a direct role in long-term potentiation, memory consolidation, and learning processes in the hippocampus and prefrontal cortex. This provides a molecular basis for the nootropic effects documented in behavioral studies that is distinct from the anxiolytic mechanisms — Selank appears to support learning and memory through dopaminergic signaling while simultaneously reducing the anxiety that impairs cognitive performance. Grade C-D (transcriptomic study; development institution; D5R's role in LTP is well-established; Selank-specific activation needs independent replication).

Selank retains the immunomodulatory properties of its parent tuftsin, including modulation of IL-6, Th1/Th2 cytokine balance, and interferon-related gene expression. Ershov et al. documented that 14 days of Selank produced measurable IL-6 changes and cytokine ratio shifts in models of GAD with neurasthenic features. This immune-neurological interface is consistent with growing evidence that anxiety disorders and immune dysregulation are bidirectionally linked. The immunomodulatory effects are probably not the primary therapeutic mechanism but may contribute to the broad-spectrum stress resilience effects users report. Grade C (Russian studies; consistent with tuftsin heritage; mechanistically coherent).

MECHANISM SUMMARY — WHAT IS AND ISN'T KNOWN

Selank's five proposed mechanisms are each plausible and each has some experimental support. What is missing is a unified mechanistic account that explains which pathways are primary, in what order they operate, what the dose-response relationship is for each, and how they interact. The enkephalinase inhibition finding (Grade C) is the most independently documented specific mechanism. The GABA-A allosteric modulation is the most commonly cited but also the least precisely characterized. The practical result — anxiolysis without sedation or dependence, with mild cognitive support — is the most consistently documented outcome across both preclinical and the limited clinical data.

INTRANASAL IS NOT OPTIONAL FOR FULL EFFICACY

Selank cannot be taken orally. GI proteases destroy it before systemic absorption. This is not preference — it is pharmacology. The intranasal route is what was used in the Russian clinical trials. It is also pharmacologically advantageous: the olfactory pathway provides direct access to CNS structures relevant to Selank's anxiolytic mechanism, bypassing the blood-brain barrier more efficiently than systemic injection for centrally acting peptides. SubQ injection distributes systemically first, then relies on the blood-brain barrier for CNS effects — a longer path. For anxiolytic and nootropic applications, intranasal is the route most consistent with the evidence.

• Intranasal spray (primary evidence route): delivers Selank to olfactory neuroepithelium with direct access to limbic and prefrontal structures relevant to anxiety modulation. Rapid onset (10-30 minutes). The commercially approved Russian formulation uses 150 mcg per actuation. Community protocols range from 250-500 mcg per session.
• SubQ injectable: highest bioavailability systemically; slower CNS onset than intranasal. Used by community members who prefer injection over nasal spray. Evidence base is extrapolated from intranasal clinical data — no dedicated SubQ Selank clinical trial exists. Practical choice when chronic sinus conditions prevent nasal administration.
• Sublingual: lowest bioavailability of the three routes. Used by some community members as a middle ground. The least studied option. If intranasal is not possible, SubQ is more evidence-supported than sublingual.

Selank has a plasma half-life of approximately 2-5 minutes due to rapid peptidase degradation. This short plasma half-life is the reason oral delivery fails and why intranasal administration leverages the olfactory pathway — direct CNS access before systemic clearance. Despite the short plasma half-life, effects last 4-8 hours per dose because downstream signaling changes (BDNF transcription, enkephalin stabilization, serotonin normalization) persist long after the parent peptide is cleared. Cumulative benefits from regular dosing develop over days to weeks as BDNF upregulation and synaptic plasticity changes accumulate. No detailed human pharmacokinetic study has been published in indexed literature. The 2-5 minute estimate is from preclinical data and is consistent across multiple sources.

For intranasal use, lyophilized Selank is reconstituted and transferred to a metered-dose nasal spray atomizer. Key preparation steps: reconstitute with bacteriostatic water, transfer using a sterile syringe into an amber glass nasal spray bottle (to protect from UV degradation), refrigerate at 2-8C, use within 30 days. The Russian approved formulation delivers 150 mcg per actuation. Community atomizers typically deliver approximately 100 mcL (0.1 mL) per actuation.

Vial Size

BAC Water

Concentration

Per 0.1 mL spray

Notes

5 mg

1.0 mL

5,000 mcg/mL

500 mcg

High concentration; community standard for nasal spray

5 mg

2.0 mL

2,500 mcg/mL

250 mcg

Lower dose per spray; better for precise titration

5 mg

5.0 mL

1,000 mcg/mL

100 mcg

Close to Russian approved formulation dose per actuation

Nasal administration technique: tilt head slightly back (do not lean forward). One spray per nostril. Wait 30 seconds between nostrils. Sniff gently — do not forcefully inhale, as this delivers the peptide to the throat rather than the olfactory mucosa. The goal is olfactory epithelium contact, not deep nasal inhalation. Many users alternate nostrils per dose session to reduce cumulative nasal irritation.

Vial Size

BAC Water

Concentration

1 unit (U-100)

Notes

5 mg

1.0 mL

5,000 mcg/mL

50 mcg

Standard injectable concentration

5 mg

2.0 mL

2,500 mcg/mL

25 mcg

Lower concentration for smaller injection volumes

Use Case

Intranasal Dose

SubQ Dose

Frequency

Cycle Length

Anxiety (acute relief)

250-500 mcg

150-250 mcg

As-needed

Single doses or short courses

Standard anxiety protocol

250-500 mcg

150-250 mcg

1-2x daily

10-14 days (Russian protocol); community often extends

Nootropic / cognitive focus

250-400 mcg

150-200 mcg

Once daily (morning)

10-14 day cycles with 1-2 week breaks

Combination with Semax

250 mcg Selank (morning)

—

Selank AM, Semax midday

10-14 day cycles

CYCLING NOTE

The Russian approved clinical protocol uses 10-14 day courses. The community often runs longer cycles (3-4 weeks) or as-needed use. No tolerance or dependence has been reported in clinical data, which makes the cycling recommendation more conservative than strictly necessary — but cycling off allows receptor sensitivity to reset and is a reasonable precaution given that long-term data beyond the clinical trial windows is limited.

Selank has a mild psychostimulant quality — not stimulant in the caffeine/amphetamine sense, but enough that evening dosing may affect sleep for some users. Morning and early afternoon dosing is the practical standard. For the Selank + Semax combination, the conventional community approach: Selank in the morning to establish a calm baseline, Semax at midday for the cognitive peak, separating the onset profiles so neither disrupts sleep.

No mandatory lab testing for standard short cycles. For users with autoimmune conditions: note the immunomodulatory effects and monitor for any changes in symptom pattern. For users taking benzodiazepines: Selank has been combined with benzos in clinical studies (the 2015 combination study showed additive benefit) — but given GABAergic overlap, be cautious about additive sedation risk at higher combined doses. Discuss with prescribing physician before combining.

Selank's safety profile in published Russian clinical data is remarkably clean. Across multiple studies spanning decades of clinical use in Russia, no serious adverse events have been documented. This contrasts sharply with the conventional anxiolytic alternatives (benzodiazepines: dependency, withdrawal, cognitive impairment; SSRIs: sexual dysfunction, emotional blunting, discontinuation syndrome; buspirone: slow onset, dizziness). The absence of serious adverse events across Russian clinical exposure is meaningful — but Western independent safety assessment has not occurred. The FDA's flagging of Selank in its safety concerns list specifically cites limited human safety information, immunogenicity risk, aggregation potential, and concerns about peptide-related impurities — not documented harms from the Russian trials.

• Nasal irritation and dryness: the most commonly reported adverse effect with intranasal use. Mild stinging upon administration; nasal dryness with repeated use. Manageable with lower concentration formulations and rotating nostrils. Some users find saline nasal rinse pre-administration reduces irritation.
• Mild taste in the back of throat: when some of the nasal spray runs posteriorly. Not harmful; managed with proper administration technique (slight head tilt back, sniff gently).
• Mild headache: occasional at higher doses or first use. Typically resolves with consistent use or dose reduction.
• Transient fatigue or sedation (rare): occasionally reported at higher doses in sensitive individuals; not a characteristic of Selank at clinical doses and inconsistent with its pharmacological profile.
• SubQ injection site: mild redness or warmth; no significant ISR pattern equivalent to GHK-Cu.

Selank is frequently marketed as 'benzo-level anxiety relief without dependence.' The clinical evidence does support comparable anxiolytic efficacy to medazepam in the Russian trial. The absence of dependence and withdrawal in clinical populations is well-documented. But the comparison needs precision: medazepam is a moderately potent benzodiazepine — not the most potent class available. The comparison was in a controlled clinical setting with supervised dosing. Whether Selank can substitute for benzodiazepines in severe anxiety disorder, in higher-dependency individuals, or in acute panic situations has not been tested. The appropriate framing: Selank appears to produce clinically meaningful anxiolytic effects comparable to moderate benzodiazepine use, without the safety concerns that make benzodiazepines problematic for long-term management. That is a genuine and important advantage. It is not a proven replacement for clinical benzodiazepine therapy in severe anxiety.

• Pregnancy and breastfeeding: no safety data; avoid.
• Active autoimmune conditions: the immunomodulatory properties (tuftsin heritage) may interact unpredictably with autoimmune disease states. Discuss with treating physician before use.
• Severe psychiatric disorders (schizophrenia, bipolar disorder with psychotic features): insufficient safety data; the modulatory effects on dopamine and serotonin systems warrant caution.
• Children: no safety data; contraindicated.

Selank occupies a unique dual regulatory position:

• Russia: approved prescription pharmaceutical. Selank 0.15% nasal drops registered by the Russian Ministry of Health in 2009. Available in Russian and some CIS country pharmacies. This is a genuine pharmaceutical approval based on completed clinical trials — different in kind from a research chemical.
• United States: research chemical, not FDA-approved. Selank acetate was on the FDA's 503A Category 2 bulk drug substances list (significant safety concerns). The FDA noted specific concerns about limited human safety data, immunogenicity risk, peptide impurities, and limited information about the proposed intranasal route. Selank acetate's nomination was withdrawn and it was removed from Category 2 — following the same pattern as BPC-157, TB-500, and KPV. It is scheduled for PCAC review on July 24, 2026 (Day 2 of the PCAC meeting, the day after BPC-157, TB-500, KPV, and MOTs-C).
• European Union: not approved, investigational. No EMA registration. No completed EU clinical trials registered.

WADA STATUS — UNCERTAIN, NOT SAFE

Selank and Semax do not appear by name on the 2026 WADA Prohibited List in S1, S2, or most other categories. However, WADA's S0 category prohibits 'any pharmacological substance which is not addressed by any of the subsequent Sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use.' Whether Russian Ministry of Health approval satisfies WADA's S0 requirement is not established — WADA has not published a formal determination on whether Russian approval counts as 'governmental regulatory health authority approval' for purposes of S0. Athletes subject to WADA testing should not assume Selank is permitted. The prudent position: treat Selank as potentially banned under S0, verify with your specific anti-doping authority, and do not use in competition without formal clearance. The 'not on the list' argument is not sufficient.

The Selank + Semax combination is the most widely discussed neuropeptide pairing in the nootropic community. The mechanistic rationale is clean: Semax is primarily a nootropic/cognitive enhancer (BDNF, AMPA receptor, dopaminergic activation); Selank is primarily an anxiolytic/stabilizer (GABA-A, enkephalinase, serotonin normalization). Semax drives cognitive performance upward; Selank prevents the anxiety that often accompanies high cognitive demand or stimulant-type activation. The combination is described by community users as 'calm focus' — the state of being cognitively engaged without anxious activation.

Protocol: Selank intranasally in the morning (250-500 mcg) to establish the calm baseline, Semax intranasally at midday (100-300 mcg) for the cognitive peak. This sequencing separates the onset profiles and prevents the mild psychostimulant quality of Semax from interfering with sleep if dosed too late. Pre-mixed Selank + Semax intranasal formulations are available from some vendors — convenient but sacrifice dosing flexibility. No controlled study has evaluated the combination, but mechanistic non-redundancy is well-supported and the community consensus is consistent across multiple independent reporters.

For users running healing peptide protocols (GLOW, KLOW, Wolverine), adding Selank addresses a non-overlapping dimension: the psychological and neurological component of recovery. Chronic pain, post-injury anxiety, and the cognitive burden of a slow recovery process are real quality-of-life impacts that the healing peptides do not address directly. Selank + GLOW or KLOW creates a comprehensive protocol covering tissue repair (BPC-157, TB-500), ECM quality (GHK-Cu), inflammation (KPV in KLOW), and psychological stability (Selank). No pharmacological conflicts exist between Selank and any GLOW/KLOW compound.

For users running GH secretagogue protocols for anti-aging or body composition, adding Selank addresses the anxiety and sleep quality dimensions that GH protocols can sometimes disrupt. CJC-1295/Ipamorelin promotes deep sleep via GH pulse optimization; Selank's anxiolytic effects can further support the parasympathetic state required for quality slow-wave sleep. These compounds operate on entirely different axes — GH vs neurological — with no mechanism overlap.

The 2015 Russian clinical study (70 patients) showed that Selank combined with a standard benzodiazepine produced better efficacy and fewer side effects than the benzodiazepine alone. This is the only compound in this book with published data specifically supporting combination with a pharmaceutical drug class. The implication: for users prescribed low-dose benzodiazepines for anxiety management, adding Selank may allow dose reduction over time. This should be done only under physician supervision — abrupt benzodiazepine reduction can cause serious withdrawal. Do not attempt to self-manage benzodiazepine tapering with Selank without medical oversight.

Timeframe

What You May Notice

10-30 minutes (intranasal)

Acute anxiolytic onset — reduced subjective anxiety, calmer thought pattern, mild relaxation without sedation. The effect is often described as a gentle quiet of the nervous system rather than a drug effect.

30-60 minutes

Peak anxiolytic effect. Cognitive function preserved or mildly enhanced. Some users report improved verbal fluency and focus — the 'calm focus' quality. SubQ users: slower onset, similar peak.

2-4 hours

Sustained anxiolytic effect per dose. Gradual return to baseline rather than abrupt offset. No rebound anxiety reported.

4-8 hours

Residual effect diminishing. Total single-dose duration varies by individual and dosing.

Days 1-7 (daily use)

Cumulative anxiolytic stabilization beginning. Baseline anxiety level gradually declining with consistent use. BDNF upregulation accumulating.

Week 2-3 (daily use)

Full cumulative effect established. Stable lower anxiety baseline. Memory and learning support effects most pronounced in this window. Sleep quality improvements commonly reported.

Post-cycle

Gradual return of baseline anxiety level over days to weeks after cessation. No withdrawal. No rebound. Return is a return to baseline, not below-baseline.

• Consistent daily dosing: BDNF upregulation and cumulative anxiolytic stabilization are dose-duration dependent. Single-dose use produces acute relief; the full profile requires consistent daily administration over the cycle.
• Morning timing: the mild psychostimulant quality makes morning administration preferable. Evening dosing after 4-5pm risks sleep interference for sensitive individuals.
• Proper intranasal technique: olfactory mucosa delivery (gentle backward-tilt head position, gentle sniff) vs throat delivery (forward lean, forceful inhalation) dramatically affects CNS delivery. Most delivery failures with intranasal Selank are technique failures.
• Reducing ambient anxiety triggers during cycle: Selank works by modulating the neurochemical basis of anxiety — it does not eliminate environmental stressors. Reducing avoidable stressors during a protocol cycle amplifies the compound's observable effect.
• Combination with Semax: for the nootropic application specifically, the Selank + Semax combination consistently outperforms either alone in community reports.

• Taking Selank orally: it will not work. GI proteases destroy it. This is not about dose — oral Selank at any dose produces negligible plasma levels.
• Administering intranasally incorrectly: tilting head forward and inhaling forcefully delivers the peptide to the throat, not the olfactory mucosa. The community's most common delivery failure mode. The correct technique: slight backward tilt, gentle spray, sniff gently.
• Using N-Acetyl Selank Amidate interchangeably with Selank: different compound, much thinner evidence base. The two are not interchangeable and vendors occasionally substitute one for the other without clear labeling. Confirm mass spec identity on COA.
• Expecting immediate long-term anxiety resolution: Selank produces acute anxiety relief per dose and cumulative stabilization over weeks. It does not permanently alter anxiety baseline. When the cycle ends, the effect fades. This makes it more like a medication than a cure, which aligns with how it is used as a prescription drug in Russia.
• Assuming WADA safety: not explicitly listed on the 2026 WADA list, but not confirmed safe under S0. Athletes who treat 'not named on the list' as 'cleared to use' are taking a real doping violation risk.

No physical dependence, no withdrawal syndrome, no rebound anxiety beyond return to individual baseline. Russian clinical protocols use 10-14 day courses followed by breaks. The community commonly extends to 3-4 week cycles. A 1-2 week break between cycles is standard community practice to maintain receptor sensitivity. The anxiety management benefit requires ongoing use — unlike GHK-Cu (where collagen changes are structural and persist post-cycle), Selank's effects are pharmacodynamic and fade when the compound is discontinued.

SOURCING CRITICAL POINT FOR SELANK

Selank is available from two very different source categories: legitimate Russian pharmacy formulations (Selank 0.15% nasal drops, manufactured by Peptogen LLC or similar) and Western research chemical vendors. Russian pharmacy products are manufactured to pharmaceutical standards and have a real quality assurance trail. Western research chemical products vary enormously. The key sourcing requirements for Western research chemical Selank: HPLC purity 99%+ (Selank's pharmacology in animal models shows significant sensitivity to purity — below 98%, truncated sequences can interfere with receptor binding); mass spectrometry confirming ~791 Da (identity confirmation, distinguishes from NA-Selank-A); endotoxin testing below 0.1 EU/mg for injectable use; batch-specific lot number. Pricing in 2026: reputable research vendor (HPLC + MS + endotoxin COA), 5 mg Selank: $45-70. Pricing for nasal formulations from compounding pharmacies (pending PCAC outcome): $100-200 per month.

Selank occupies a specific and consistent community niche: users who have either had bad experiences with benzodiazepines (dependence, tolerance, cognitive fog) or who want anxiety management without the side effect profile of pharmaceutical options. The community character is somewhat different from the healing peptide users — more focused on mental health, cognitive performance, and biohacking, less on athletic recovery. The Selank + Semax pair is treated as a foundational nootropic stack with a degree of consensus comparable to the Wolverine Stack in the healing community.

The consistent subjective description across community reports: 'calm but alert,' 'background anxiety reduced without feeling sedated,' 'can think more clearly because the noise is quieter.' This profile is remarkably consistent and distinguishes Selank sharply from benzodiazepines (which are calming but cognitively blunting), SSRIs (which work slowly and cause sexual dysfunction), and beta-blockers (which block physical symptoms but not cognitive anxiety). The community has effectively self-organized around a compound that no Western pharmaceutical company has brought to market, because the combination of properties it offers does not cleanly fit existing drug class categories.

Intranasal: mild stinging sensation upon application in some users; resolves within 30-60 seconds. No taste if technique is correct (head tilted back); slight bitter taste in throat if compound runs posterior, indicating delivery to throat rather than olfactory mucosa. The anxiolytic onset is notable primarily by what it takes away: racing thoughts slow, physical tension reduces, the sense of threat or urgency in the background of consciousness quiets. Most first-time users describe it as subtle rather than dramatic — 'like turning down the volume on anxiety' rather than 'feeling high' or sedated. Users who experience stronger effects typically have higher baseline anxiety.

Myasoedov NF, et al. Development of new generation regulatory peptides on the basis of tuftsin fragments. Development of Selank (TP-7). Institute of Molecular Genetics RAS. [Original development series]

Seredenin SB, Kozlovskaya MM, Blednov YA, et al. (1998) [1]. The anxiolytic action of an analog of the endogenous peptide tuftsin on the model of 'anxiety' in mice. Zh Vyssh Nerv Deiat Im I P Pavlova. 48(1):153-160. [First animal anxiolytic demonstration]

Kost NV, Sokolov OY, Gabaeva MV, et al. (2001). Semax and Selank inhibit the enkephalin-degrading enzymes from human serum. Biomed Khim. 47(6):632-637. [Enkephalinase inhibition mechanism — dose-dependent; greater potency than bacitracin and puromycin]

Meshavkin VK, Kost NV, Sokolov OY, et al. (2006). Selank action on opioid system is mediated by enkephalinase inhibition. Bull Exp Biol Med. 142(5):575-577. [Confirms opioid system effects via enkephalinase pathway]

Zozulya AA, Kost NV, Sokolov OY, et al. (2008). Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 108(4):38-48. PMID: 18454096. [THE pivotal clinical trial — 62 patients, GAD and neurasthenia, Selank vs medazepam; comparable anxiolytic; + antiasthenic; enkephalin half-life correlation]

Seredenin SB, Blednov YA, Badyshtov BA, et al. (2009) [5]. Clinical registration study. Russian Ministry of Health Registration of Selank 0.15% nasal drops for GAD and neurasthenia. [Russian regulatory approval]

Kasian VS, et al. (2015/2016). Transcriptomic analysis of Selank effect on rat brain. PMID: 26847159. [Microarray study; Drd5 activation; serotonin/GABA/opioid gene modulation — development institution]

Institute of Molecular Genetics (2017). BDNF mRNA expression study — 40% upregulation in hippocampus with Selank; spatial memory improvement; LTP enhancement. [Development institution; not independently replicated]

Uchakina ON, Uchakin PN, et al. BDNF neuroprotection in chronic alcohol models. [Preclinical; BDNF mechanism in dependency context]

Nadorova AV, et al. Selank serotonin effects are state-dependent: normalizes pathologically elevated 5-HT in frontal cortex, hypothalamus, and amygdala; no change under normal baseline. [Development institution; animal model]

FDA. Selank acetate — removed from 503A Category 2 bulk drug substances list. PCAC review scheduled July 24, 2026. FDA cited: limited human safety data, immunogenicity risk, peptide impurities, limited information on intranasal route.

WADA. (2026). Prohibited List. S0 category: non-approved substances. Selank not explicitly listed; S0 coverage uncertain given Russian approval status.

Well-suited for: adults with generalized anxiety, social anxiety, or high-stress periods seeking relief without sedation, dependence risk, or cognitive impairment; users who have had adverse experiences with benzodiazepines and are seeking an alternative with a different mechanism; users running Selank + Semax as a nootropic combination targeting calm focus; users running healing peptide protocols who want to address the psychological/neurological dimension of recovery alongside the physical.

Extra caution for: athletes subject to WADA testing (S0 coverage uncertain — verify with your anti-doping authority before use); individuals with active autoimmune conditions (immunomodulatory effects warrant physician discussion); users planning to reduce prescribed benzodiazepines (medical supervision required for any benzo taper — do not self-manage).

Not appropriate for: anyone expecting Selank to permanently resolve anxiety disorders (effects are pharmacodynamic and return to baseline after cycling off); anyone treating severe anxiety episodes requiring rapid pharmaceutical-grade intervention without medical oversight; oral administration (it will not work).

Goal

Choose

Primary anxiety relief without sedation

Selank

Primary cognitive enhancement / focus

Semax

Calm focus (anxiety + cognition simultaneously)

Selank + Semax combination

Neuroprotection after stroke or ischemic event

Semax (stronger clinical evidence for neurological protection)

Sleep quality improvement

Selank (anxiolytic effect supports parasympathetic state)

Post-workout or athletic recovery

Semax (BDNF; tissue protection; broader clinical evidence base)

• 'Approved in Russia' = proven: Russian Ministry of Health approval is genuine evidence. It is not the same as FDA approval, EMA approval, or independent Phase 3 RCT data. The quality of the Russian regulatory process for peptides and the independence of the clinical data are both meaningful questions that cannot be evaluated from outside the Russian regulatory system.
• 'Not on the WADA list' = safe to use in competition: the S0 category is a blanket prohibition on unapproved substances. Selank's Russian approval may or may not satisfy the S0 exemption criteria. WADA has not clarified. Athletes who assume absence from the explicit list means they are safe are making an assumption without formal basis.
• Selank replaces psychiatric medication: Selank may provide meaningful anxiety management as a component of a broader approach. It is not a validated substitute for prescribed psychiatric medication in diagnosed anxiety disorders. Anyone managing anxiety with pharmaceutical support should involve their prescribing physician before modifying their treatment.
• Selank and Semax are the same or interchangeable: different sequences, different mechanisms, different clinical profiles. Selank = anxiolytic primary, nootropic secondary. Semax = nootropic primary, neuroprotective, minimal anxiolytic. The confusion is understandable given shared Russian origin and intranasal route but they are distinct compounds.

— End of Selank —

THE PEPTIDE BIBLE | Selank | For Research & Educational Purposes Only